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Available online 18 March 2019Background: South Africa has the largest public antiretroviral therapy (ART) programme in the world. We
assessed temporal trends in pretreatment HIV-1 drug resistance (PDR) in ART-naïve adults from South Africa.
Methods: We included datasets from studies conducted between 2000 and 2016, with HIV-1 pol sequences from
more than ten ART-naïve adults. We analysed sequences for the presence of 101 drug resistance mutations. We
pooled sequences by sampling year and performed a sequence-level analysis using a generalized linear mixed
model, including the dataset as a random effect.
Findings: We identiﬁed 38 datasets, and retrieved 6880 HIV-1 pol sequences for analysis. The pooled annual
prevalence of PDR remained below 5% until 2009, then increased to a peak of 11·9% (95% conﬁdence interval (CI)
9·2-15·0) in 2015. The pooled annual prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) PDR
remained below 5% until 2011, then increased to 10.0% (95% CI 8.4–11.8) by 2014. Between 2000 and 2016, there
was a 1.18-fold (95% CI 1.13–1.23) annual increase in NNRTI PDR (p b 0.001), and a 1.10-fold (95% CI 1.05–1.16)
annual increase in nucleoside reverse-transcriptase inhibitor PDR (p = 0.001).
Interpretation: Increasing PDR in South Africa presents a threat to the efforts to end the HIV/AIDS epidemic. These
ﬁndings support the recent decision to modify the standard ﬁrst-line ART regimen, but also highlights the need
for broader public health action to prevent the further emergence and transmission of drug-resistant HIV.
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Research in context
Evidence before this study
We searched PubMed for systematic reviews and meta-analyses
of pretreatment or transmitted HIV drug resistance in South
Africa. We used the search terms “HIV” AND “South Africa” AND
“drug resistance” AND “(systematic review OR meta-analysis)”.
We found twometa-analyses exploring regional prevalence of pre-
treatment or transmitted HIV drug resistance, where data from
South Africa were combined with data from other countries in a
regional analysis (southern Africa or sub-Saharan Africa). We
found a meta-analysis of pretreatment HIV drug resistance in chil-
dren younger than 12 years, which included data from South
Africa. We also had a systematic review from our own group
which analysed transmitted drug resistance in South Africa up to
2010. We did not identify any studies that focused on South
Africa and incorporated sequences collected since 2010, when
scale-up of antiretroviral therapy accelerated.
Added value of this study
In this pooled analysis of 6880 HIV-1 sequences from 38
datasets, we provide up-to-date estimates of the prevalence of
pretreatment HIV drug resistance (PDR) in South Africa. We pres-
ent evidence of increasing PDR, particularly since the acceleration
of ART scale-up in 2010. We demonstrate that the increase is
largely driven by non-nucleoside reverse-transcriptase inhibitor
(NNRTI) PDR, but that levels of nucleoside reverse-transcriptase
inhibitor (NRTI) PDR are also rising. In particular, we note a
concerning increase in the prevalence of tenofovir resistance-
associatedmutations (TRAMs),which could have important impli-
cations for current treatment and prevention strategies.
Implications of all the available evidence
Our findings provide clear evidence that PDR in South Africa has
reached the threshold at which the World Health Organization rec-
ommends urgent public health action (NNRTI PDR N10%). Whilst
our data provide support for the decision to move to a new
dolutegravir-based first-line regimen, they also highlight the broader
need to improve quality of HIV treatment and prevention if
South Africa is to achieve the Joint United Nations Programme on
HIV/AIDS goal of ending AIDS by 2030.
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The roll-out of antiretroviral therapy (ART) has been a major break-
through in the global response to HIV, helping to reduce HIV-related
deaths by 48% between 2005 and 2016, and new HIV infections by
11% between 2010 and 2016 [1]. Despite these impressive public health
gains, substantial expansion of access to ARTwill be required to achieve
the target of ending the HIV epidemic by 2030 [1]. The emergence
and transmission of HIV drug resistance (HIVDR) pose a threat to the
successful treatment and prevention of HIV, and there is now strong
evidence that levels of HIVDR are increasing substantially in southern
Africa [2], the region that faces the greatest challenges to ending the
HIV epidemic.
Pretreatment HIV drug resistance (PDR) is drug resistance in a
person initiating or re-initiating ART (i.e. with or without prior ART
exposure) [3,4]. PDR can arise in one of three ways: transmission of
drug-resistant HIV from a person with acquired drug resistance (ADR);
transmission of primary drug-resistant HIV from another ART-naïveperson; or ADR resulting from prior exposure to antiretroviral drugs for
treatment or prevention. The presence of PDR is associated with poorer
virological outcomes on ﬁrst-line ART [5,6].
South Africa, with over sevenmillion people livingwith HIV (PLHIV)
in 2016, accounts for almost one in ﬁve PLHIV globally [1]. The country
has the largest public ART programme in theworld, withmore than four
million people on ART by early 2018 [7]. In the ﬁrst few years of ART
rollout, the levels of PDR were low (b5%) [8]. More recent studies,
conducted since the accelerated expansion of ART coverage in 2010,
have suggested higher levels of PDR [9,10].
Given this evidence of rising levels of PDR in the country and the
wider region, and the continued expansion of ART for treatment and
prevention, we performed a pooled analysis of HIV sequence data
from South Africa, ﬁrstly to determine the annual trends in PDR and
secondly to explore in detail the patterns of observed drug resistance
mutations (DRMs).
2. Methods
2.1. Search Strategy and Selection Criteria
This study was a systematic review and pooled analysis aimed at de-
termining trends in PDR amongst ART-naïve adults in South Africa. We
conducted and reported this in line with the Preferred Reporting Items
for Systematic Reviews andMeta-Analyses statement (checklist included
in Appendix, p 1) [11]. To identify relevant studies we ﬁrst searched for
published articles in MEDLINE using the OvidSP interface on 12 Septem-
ber 2017 (Appendix, p 3). We then scanned the reference lists of all arti-
cles selected for inclusion and conducted forward citation searches using
Google Scholar. Finally, we searched South African HIV-1 sequence
datasets not linked to a published article, using the PopSet database on
the National Center for Biotechnology Information website [12].
We included studies involving adults (deﬁned for the purpose of this
analysis as 15 years or older) in South Africa with recent or chronic HIV
infection and no documented prior ART exposure. We obtained infor-
mation about prior ART exposure from either the article or the sequence
annotation in GenBank.We excluded studies that enrolledwomenwith
documented exposure to antiretrovirals for prevention of mother-to-
child transmission (pMTCT). We excluded studies with fewer than ten
HIV-1 pol sequences; and studies where the sequences were generated
from samples collected prior to 2000.Where articles reported onmulti-
ple separate cross-sectional studies (for example a series of annual an-
tenatal surveys), we separated the sequences into individual datasets
according to the sampling year. If results from the same studywere pre-
sented in more than one publication, we pooled the sequences into a
single dataset. We included sequences from one multi-national study
[13], as South African sequences could be identiﬁed through the se-
quence annotation in GenBank.
From the articles, we retrieved a core set of information, including
the year(s) of sample collection, province, study type, study population,
proportion of participants that were female, and method for determin-
ing prior ART exposure.
2.2. Sequence Analysis
Wedownloaded publicly available sequences for the included studies
from GenBank [12]. Where sequences were not publicly accessible, we
contacted the study authors to request the sequences.We aligned and vi-
sually inspected the sequences in AliView v1.18 (http://ormbunkar.se/
aliview/) [14]. We manually edited the sequences until perfect codon-
based alignments were produced. We assessed sequences for their
completeness and quality using the Calibrated Population Resistance
(CPR) tool (http://cpr.stanford.edu/cpr.cgi) [15]. Stop codons, frame-
shiftmutations, APOBEC3G/F hyper-mutations, highly unusualmutations
and highly ambiguous nucleotides (B, D, H, V and N), were all used as
indicators of poor sequence quality. We excluded from the analysis any
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[14]. We included all sequences that had complete reverse transcriptase
gene (RT) sequences (codons 40 to 240), with or without complete
protease (PR) sequences. Where multiple sequences were identiﬁed
from the same study participant (for example in cohort studies), we
only included the sequence from the earliest time point. Most sequences
were not annotated with information about participant sex or age, so we
did not include this information in the datasets.
We deﬁned PDR as the presence of any of 101 DRMs. The mutation
list included the 93 mutations from the World Health Organization
(WHO) 2009 list of surveillance drug-resistance mutations (SDRMs)
[16]; and eight additional tenofovir (TDF) resistance-associated muta-
tions (TRAMs) characterised in a recent international collaborative anal-
ysis (A62V, K65N, S68GDN, K70QT, and V75L) [17], (Appendix, p 4).
Overall, the mutation list encompassed 42 nucleoside reverse-
transcriptase inhibitor (NRTI)-resistance mutations at 17 RT posi-
tions, 19 non-nucleoside reverse-transcriptase inhibitor (NNRTI)-re-
sistance mutations at ten RT positions, and 40 protease inhibitor (PI)-
resistance mutations at 18 PR positions. We used the CPR tool to calcu-
late the proportion of sequences with overall and drug class-speciﬁc
PDR [15].
2.3. Trends in Pretreatment Drug Resistance
To assess the annual increase in overall and drug class-speciﬁc PDR,
we pooled sequences fromdifferent studies by year of sample collection
and performed a generalized linear mixed regression model using theFig. 1. Flow diagram of articles and datasets identiﬁed and selected for the pooled sR package (v3.3.1) lme4. We used the presence or absence of PDR
(or drug class-speciﬁc PDR) as the binary outcome variable and the
sampling year as the explanatory variable. Where samples from the
same study had been collected over more than one year and where
the sequence annotation did not include year of sample collection, we
allocated the sequences to the median sampling year. To account for
heterogeneity between studies, we included the dataset as a random
effect in the model. Given the relatively small number of sequences
with speciﬁc mutations, we also pooled the sequences into three
periods (2000–2008, 2009–2012, and 2013–2016) and checked for
any trend in prevalence of speciﬁc NRTI- and NNRTI-resistance muta-
tions using the chi-squared test for trend.3. Results
We initially identiﬁed 856 articles through our database search and
nine articles through other sources. After removing duplicate publica-
tions, we screened 790 abstracts and assessed 46 full-text articles for el-
igibility. We excluded 14 articles on the basis of our eligibility criteria:
eight contained fewer than 10 HIV-1 pol sequences; two had only PR
sequences with no RT sequences; one reported on a duplicate sequence
dataset; one contained only sequences generated from samples collected
prior to 2000; one was based on targeted sequencing for a single muta-
tion (K65R); and sequences were unavailable for one study (Appendix,
p 5). From the 32 articles, we identiﬁed 38 datasets with at least ten
HIV-1 pol sequences from ART-naïve adults (Fig. 1, Table 1, Appendix,equence analysis of PDR in antiretroviral therapy-naive adults in South Africa.
Table 1
Characteristics of included datasets with ten or more RT sequences from ART-naïve adults.
Dataset
ID
Source Sampling
years
Province(s) Study type Study population Proportion
females
Method for
determining
prior ART use
Met criteria for
WHO TDR/PDR
survey
1 Bessong 2001 LP Genetic diversity ART-naïve adults 79% NS No
2 Bessong 2001–2004 GT, LP TDR ART-naïve adults 68% NS Yes
3 Chimukangara 2013 KZN Population HIV
surveillance
HIV-positive adults
N15 years
73% Linkage to public
sector records
No
4 Chimukangara 2014 KZN Population HIV
surveillance
HIV-positive adults
N15 years
75% Linkage to public
sector records
No
5 Chimukangara 2014–2015 KZN Population HIV
surveillance
HIV-positive adults
15–49 years
66% Self-report No
6 Gordon 2001–2002 KZN Genetic diversity ART-naïve adults 66% NS No
7 Hamers 2007–2008 GT, MP PDR Adults eligible for ART 62% Self-report Yes
8 Huang 2006 FS TDR ART-naïve adults NS Self-report Yes
9 Hunt 2005 GT, KZN ANC survey Primigravid female
b25 years
100% NS Yes
10 Hunt 2006 GT, KZN ANC survey Primigravid female
b25 years
100% NS Yes
11 Hunt 2007 GT, KZN ANC survey Primigravid female
b25 years
100% NS Yes
12 Hunt 2008 GT, KZN ANC survey Primigravid female
b25 years
100% NS Yes
13 Hunt 2009 GT, KZN ANC survey Primigravid female
b25 years
100% NS Yes
14 Hunt 2010 GT, KZN ANC survey Primigravid females
≤21 years
100% NS Yes
15 Hunt 2011 EC, FS, GT, KZN,
WC
ANC survey Primigravid females
≤25 years
100% NS Yes
16 Hunt 2012 EC, FS, GT, KZN, LP,
MP, NC, NW, WC
ANC survey Primigravid females
≤21 years
100% NS Yes
17 Iweriebor 2007–2008 LP Genetic diversity ART-naïve adults 90% Self-report No
18 Jacobs 2002–2004 WC Genetic diversity ART-naïve adults 66% Self-report No
19 Jacobs 2008–2010 WC Neurocognitive study ART-naïve females 100% NS No
20 Manasa 2010 KZN Population HIV
surveillance
HIV-positive adults
N15 years
85% NS No
21 Manasa 2011 KZN Population HIV
surveillance
HIV-positive adults
N15 years
76% Linkage to public
sector records
No
22 Manasa 2012 KZN Population HIV
surveillance
HIV-positive adults
N15 years
71% Linkage to public
sector records
No
23 Matthews 2000–2004 KZN Chronic infection
cohort
ART-naïve adults 92% Self-report No
24 Msimanga 2009 MP Genetic diversity ART-naïve adults 95% Self-report No
25 Musyoki 2007 GT Genetic diversity Adults initiating ART NS Self-report No
26 Nwobegahay 2008 LP TDR ART-naïve adults 70–73% Self-report Yes
27 Papathanasopoulos 2006–2007 GT Genetic diversity ART-naïve adults 74% Self-report No
28 Parboosing 2009 KZN TDR Primigravid female
b22 years
100% NS Yes
29 Parikh 2010–2011 KZN Trial screening
(HIV prevention)
Females 18–40 years
ﬁrst positive test
100% NS No
30 Pillay 2000 GT Trial screening
(pMTCT)
ART-naïve pregnant
females
100% NS No
31 Pillay 2002 GT ANC survey Primigravid females
b22 years
100% NS Yes
32 Pillay 2004 GT ANC survey Primigravid females
b22 years
100% NS Yes
33 Seoighe 2003–2005 GT, KZN Trial baseline (pMTCT) Pregnant females 100% NS No
34 Steegen 2013–2014 EC, FS, GT, KZN, LP,
MP, NC, NW, WC
PDR Adults initiating ART
or in pre-ART care
59% Self-report Yes
35 Treurnicht 2004–2005 KZN Acute infection study Females with
documented acute
infection
100% NS No
36 van Zyl 2016–2017 WC PDR ART-naïve adults
initiating ART
52% Self-report Yes
37 Wilkinson 2000 WC Phylogenetic study ART-naïve patients NS NS No
38 Wilkinson 2004 WC Phylogenetic study ART-naïve patients NS NS No
ANC, antenatal care; ART, antiretroviral therapy; EC, Eastern Cape; FS, Free State; GT, Gauteng; KZN, KwaZulu-Natal; LP, Limpopo; MP, Mpumalanga; NC, Northern Cape; NS, not stated;
NW, North West; PDR, pretreatment drug resistance; pMTCT, prevention of mother-to-child transmission; TDR, transmitted drug resistance; WC, Western Cape.
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of PDR or transmitted drug resistance.
We retrieved 7025 RT sequences and 6501 PR sequences. We
excluded 145 RT sequences and 207 PR sequences that did not meet se-
quence quality criteria. Therefore, we included 6880 RT sequences and
6294 PR sequences in the analysis (i.e. 6294 sequences with combinedPR and RT and 586 with RT only) (Appendix, pp. 10, 11). The majority
of sequences were subtype C (99.2%). Overall, 478 of 6880 sequences
(6.9%) had at least one DRM. The majority of these sequences had only
NNRTI-resistance mutations (289/478, 60.5%); dual class NRTI and
NNRTI PDR were present in 79/478 (16.5%) (Appendix, p 12). The prev-
alence of overall and drug class-speciﬁc PDR in each dataset is displayed
Fig. 2. Prevalence of pretreatment HIV drug resistance by year of sampling. A) Overall, B) non-nucleoside reverse-transcriptase inhibitor, C) nucleoside reverse-transcriptase inhibitor,
D) protease inhibitor. Each bubble represents a dataset and the size of the bubble is proportional to the number of sequences in the dataset. The sampling year is shown on the
horizontal axis and the percentage PDR on the vertical axis. PDR, pretreatment HIV drug resistance.
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speciﬁc PDR by year is shown in Table 2. The prevalence of NNRTI PDR
remained below 5% until 2011 and then increased rapidly to above 10%
by 2014. The pooled prevalence of NRTI PDR and PI PDR remained
below 5% across all years. Over the entire study period (2000–2016),
there was a 1.10-fold yearly increase in the odds of PDR (95% conﬁdence
interval (CI) 1.06–1.15), which was driven by increasing NNRTI PDR
(odds ratio (OR) 1.18, 95% CI 1.13–1.23) and NRTI PDR (OR 1.10, 95% CI
1.05–1.16) (Table 3).
Overall, 374 sequences (5.4%) had at least oneNNRTI DRM(Appendix,
p 13). The most prevalent mutation was K103NS, occurring in 278Table 2
Pooled prevalence of pretreatment HIV drug resistance (PDR), NNRTI PDR, and NRTI PDR, by y
Year Number of RT sequences Any DRM Any PDR (95% CI)
2000 66 0 –
2001 69 2 2.9 (0.4–10.1)
2002 424 26 6.1 (4.0–8.9)
2003 90 2 2.2 (0.3–7.8)
2004 377 16 4.2 (2.4–6.8)
2005 113 1 0.9 (0–4.8)
2006 303 5 1.7 (0.5–3.8)
2007 748 32 4.3 (2.9–6.0)
2008 290 13 4.5 (2.4–7.5)
2009 172 7 4.1 (1.7–8.2)
2010 306 17 5.6 (3.3–8.7)
2011 953 54 5.7 (4.3–7.3)
2012 788 60 7.6 (5.9–9.7)
2013 370 36 9.7 (6.9–13.2)
2014 1255 142 11.3 (9.6–13.2)
2015 497 59 11.9 (9.2–15.0)
2016 59 6 10.2 (3.8–20.8)
CI, conﬁdence interval; DRM, drug resistance mutation; NRTI, nucleoside reverse-transcriptase
resistance; RT, reverse transcriptase.sequences (58.2% of sequences with any DRM; 4.0% of all sequences)
(Fig. 3). In the majority of these sequences (218/278), K103NS was the
only DRM. Other common NNRTI-resistance mutations included
V106AM (n = 47), Y181C (n = 34), K101EP (n = 29) and G190ASE
(n = 27). Overall, 77/374 (20.6%) had more than one NNRTI DRM,
most commonly K103N + P225H (n = 16) and K103N + V106M
(n = 12). The prevalence of some speciﬁc NNRTI-resistance mutations
increased over time. This trend was most marked for the K103NS
and V106AM mutations, and less so for the K101EP mutations.
There was no evidence of changing prevalence of Y181C or G190ASE
(Appendix, p 14).ear.
NNRTI DRM NNRTI PDR (95% CI) NRTI DRM NRTI PDR (95% CI)
0 – 0 –
2 2.9 (0.4–10.1) 0 –
8 1.9 (0.8–3.7) 9 2.1 (1.0–4.0)
2 2.2 (0.3–7.8) 0 –
9 2.4 (1.1–4.5) 7 1.9 (0.7–3.8)
1 0.9 (0–4.8) 0 –
4 1.3 (0.4–3.3) 1 0.3 (0–1.8)
21 2.8 (1.7–4.3) 5 0.7 (0.2–1.6)
7 2.4 (1.0–4.9) 5 1.7 (0.6–4.0)
6 3.5 (1.3–7.4) 2 1.2 (0.1–4.1)
12 3.9 (2.0–6.7) 6 2.0 (0.7–4.2)
45 4.7 (3.5–6.3) 16 1.7 (1.0–2.7)
47 6.0 (4.4–7.9) 17 2.2 (1.3–3.4)
31 8.4 (5.8–11.7) 16 4.3 (2.5–6.9)
126 10.0 (8.4–11.8) 38 3.0 (2.2–4.1)
48 9.7 (7.2–12.6) 12 2.4 (1.3–4.2)
5 8.5 (2.8–18.7) 1 1.7 (0–9.1)
inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PDR, pretreatment drug
Table 3
Annual change in odds of pretreatment HIV drug resistance, 2000–2016.
Drug class Odds ratio (95% CI) p value
NRTI 1.10 (1.05–1.16) 0.0001
NNRTI 1.18 (1.13–1.23) b0.0001
PI 0.96 (0.89–1.04) 0.3650
Overall 1.10 (1.06–1.15) b0.0001
CI, conﬁdence interval; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nu-
cleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
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71 sequences (14.9% of sequences with any DRM; 1.0% of all sequences)
(Appendix, p 15). Most of the sequences with M184VI had at least one
NNRTI DRM (66/71) and just under half had additional NRTI DRMs
(31/71). The other NRTI DRMs accompanying M184VI included thymi-
dine analogue mutations (TAMs, n = 11), TRAMs (n = 11), L74VI
and/or Y115F (n = 7), and other multi-NRTI mutations (n = 2).
Classical TAMs (M41L, D67N, K70R, L210W, T215FY, and K219EQ)
were detected in 36 sequences (7.5% of sequences with any DRM;
0.5% of all sequences). The majority of these (30/36) had a single
TAM; and eleven sequences had the M41L mutation alone without
other DRMs. Overall, TRAMs were detected in 37 sequences (7.7% of
sequences with any DRM; 0.5% of all sequences). The TRAM most fre-
quently detected was K65R (n = 21). Twelve sequences had a TRAM
not on the WHO SDRM list (A62V, n = 10; K70T, n = 2), although in
four of these sequences the mutation was present with the K65R
mutation. The prevalence of TRAMs increased in later time periods:
0.1% (3/2480) in 2000–2008, 0.5% (11/2219) in 2009–2012, and 1.1%
(23/2181) in 2013–2016, and for the M184VI mutation: 0.2% (4/2480)
in 2000–2008, 0.9% (20/2219) in 2009–2012, and 2.2% (47/2181) in
2013–2016 (p b 0.001, χ2 test for trend) (Appendix, p 14).
Fifty-six sequences (0.9%) had at least one PI DRM. The most fre-
quently observed mutation was the relatively non-polymorphic M46IL
mutation, whichwas detected in 35 sequences (0.6%) (Appendix, p 16).4. Discussion
In this pooled analysis with more than 6000 HIV-1 sequences from
ART-naïve adults in SouthAfrica,we observed a sustained increase in pre-
treatment HIV drug resistance between 2000 and 2016, driven primarily
by NNRTI-resistance. The increase in PDR seems to have accelerated since
2010, which coincides with the rapid expansion of ART coverage in the
country from just 20% in 2010 to 56% in 2016 [45]. By 2014, the pooledFig. 3. Prevalence of speciﬁc mutations in HIV-1 sequences with any drug resistance
mutation. Mutations shown on the horizontal axis include all mutations observed in
N1% of the sequences with any drug resistance mutation. DRM, drug resistance mutation.prevalence of NNRTI PDR had reached 10%, the threshold at which the
WHO now recommends urgent public health action [46]. There was
also some evidence of increasing NRTI PDR, particularly TDF-associated
resistance and the M184VI mutation associated with lamivudine (3TC)
and emtricitabine (FTC) resistance. However, the pooled prevalence of
NRTI-resistance remained low (b5%) in each sampling year.
These ﬁndings are consistent with those from recent meta-analyses
exploring drug resistance across Africa, which showed levels of
resistance rising to moderate levels about ten years into the scale-up of
ART in the region [2,47]. The overall 11% annual increase in odds of
PDR between 2000 and 2016 in South Africa is comparable to the 12%
increase in odds of transmitted drug resistance across sub-Saharan
Africa between 2000 and 2013 [47]. The 18% annual increase in odds of
NNRTI PDR is somewhat lower than the 24% reported for the southern
Africa region in amore recentmeta-analysis [2]. That could be explained
by the fact that we only included ART-naïve adults, whereas the regional
meta-analysis included a small number of sequences from people with
prior ART exposure. Alternatively, it could be that the higher rate of
increase in PDR in the regional meta-analysis was reﬂective of higher
levels of PDR in other southern African countries.
Our analysis was restricted to ART-naïve individuals and our
assumption is therefore that transmitted drug resistance is the primary
driver of the increasing PDR prevalence. There are limitations to this
assumption, best illustrated by the most prevalent DRM, the K103NS
mutation. This mutation, selected by efavirenz (EFV) and nevirapine
(NVP), is the most common acquired NNRTI DRM in people with viro-
logical failure on standard ﬁrst-line ART regimens in South Africa [48].
Viruses with the K103NS mutation have transmission ﬁtness similar to
wild-type virus [49,50], and can persist for years in the infected host
[51]. It's therefore entirely plausible that the high prevalence of this
mutation is a consequence of frequent transmission. However, K103NS
is also the most common mutation to emerge in women who receive
single-dose NVP for the prevention of mother-to-child transmission
and, in this context too, the mutation can persist for years in the absence
of antiretroviral therapy [52,53]. Although we restricted the analysis to
ART-naïve individuals, we could not be certain that participants in the
individual studies were truly ART naïve. Most studies relied on self-
report of antiretroviral use, which can be unreliable [54–59]. Given that
the majority of sequences were from women, it is possible that some of
the NNRTI-resistance arose from prior exposure to NVP for pMTCT rather
than from transmitted drug resistance.
We also revealed evidence of increasing NRTI-resistance, at a rate
similar to that observed in the larger regional meta-analyses [2,47].
We speciﬁcally demonstrated increasing prevalence of TRAMs and the
M184VImutation,which is of some concern as TDF and FTC/3TC remain
the NRTI backbone of choice for ﬁrst-line ART regimens. In the latter
years (2013–2016), the pooled prevalence of the M184VI mutation
was approximately 2% and the prevalence of TRAMs was 1%. TDF and
FTC/3TC have been part of the standard ﬁrst-line ART regimen in
South Africa since 2010. The national drug resistance survey in
2013–14 showed that most people with virological failure on ﬁrst-line
NNRTI-based ART harboured the M184VI mutation and about half had
TRAMs [48]. Whilst our ﬁndings could be a signal of increasing trans-
mission of NRTI-resistant virus, we urge some caution in interpretation.
Viruses with the M184VI and K65R mutations are thought to be infre-
quently transmitted due to low transmission ﬁtness [49,50]. If they
are transmitted, the mutations revert rapidly in the absence of drug
pressure [51,60]. It is possible that some of the sequences with NRTI
resistance were obtained from people who reported themselves to be
ART naïve but who had previously been exposed to NRTIs. This is
certainly plausible as there is an increasing frequency of cyclical engage-
ment in care as ART programmes havematured [61]. Somewhat against
that was the observation that the prevalence of TAMs did not change
and remained very low (b1%) throughout the study period, although
this may be a reﬂection of the diminished use of stavudine and zidovu-
dine in ﬁrst-line regimens.
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SDRM list, but that are associated with TDF selection pressure [17].
We did identify sequences with these TRAMs, in particular the A62V
mutation, which was present both with and without the signature
K65Rmutation. Further work is required to understand the signiﬁcance
of these mutations and their effect on response to TDF-based regimens.
Without appropriate action, PDR at the levels we have documented
would be likely to have a signiﬁcant impact on the HIV epidemic in
South Africa. One mathematical model suggested that with PDR preva-
lence ≥10% and no change in the rates of resistance acquisition and
transmission, 16%more AIDS deaths each year, 9% higher HIV incidence,
and 8% higher ART costs would be attributable to drug resistance in
Africa between 2016 and 2030 [62]. Once prevalence of NNRTI PDR ex-
ceeds 10%, the WHO recommends that national programmes consider
switching to an alternative non-NNRTI ﬁrst-line ART regimen [46].
Many countries, including South Africa, have taken the decision to transi-
tion to a new ﬁrst-line regimen of co-formulated generic TDF, 3TC and
dolutegravir (DTG) [63]. This is the option that mathematical models
have predicted will mitigate the effects of HIVDR, will produce the
greatest health beneﬁts and reduce overall programme costs [64,65].
However, there remain unanswered questions around DTG in the South
African context, and strengthening of HIVDR surveillance and response
systems will still be important to maximise the impact of the new regi-
men [66,67].
An alternative approach to themodiﬁedﬁrst-line ART regimenwould
be to introduce pretreatment HIVDR testing and shift towards
individualised drug regimens [46]. Whilst there is some evidence that
HIVDR testing can be implemented in a research setting in South Africa
[68], there is no evidence that it can be delivered cost-effectively through
the public health system. The shift towards more rapid initiation of ART
(including same-day initiation) would make it particularly challenging
to deliver pretreatment HIVDR testing.We still lack simple, rapid, and in-
expensive HIVDR assays, although there are promising technologies in
development [69]. Given the increasing complexity of HIV care and the
uncertainty about the long-term effectiveness of DTG-based regimens,
there is still a need to develop and evaluate HIVDR assays and pretreat-
ment HIVDR testing strategies.
We believe it would be a mistake to think that modifying the ﬁrst-
line ART regimen is an adequate response on its own to the rising levels
of PDR. Whilst there will clearly be a reduced risk of drug resistance
emergence with DTG-based regimens, the public health approach to
ART creates scenarios where the risk may be higher, particularly
where DTG is the only fully active agent in the regimen [66,67]. The in-
creasing prevalence of PDR reﬂects weaknesses in prevention, treat-
ment, and care. Although South Africa implements routine viral load
monitoring for people on ART, there are critical gaps in the viral load
testing cascade and long delays in switching peoplewith virological fail-
ure to second-line regimens [70]. This means there is probably an
expanding pool of people with acquired HIVDR who can then transmit
drug-resistant virus to susceptible individuals. Our ﬁndings therefore
support calls to focus on improving the quality of HIV services [71].
This needs to be rooted within a broader multisectoral response, in-
formed by high quality transdisciplinary research, that addresses the so-
cial and structural drivers of the epidemic [72].
Interpretation of our ﬁndings should be subject to some limitations
beyond those already discussed. Firstly, certain provinces were over-
represented in our analysis, particularly KwaZulu-Natal and Gauteng,
and estimates from the latter years were dominated by two large
population-based surveillance studies from KwaZulu-Natal. Findings
from the national PDR survey in 2013–14 suggested substantial hetero-
geneity between the provinces in levels of PDR, and therefore our
estimates may not reﬂect the situation throughout the country [9]. Sec-
ondly, we pooled results from a number of individual studies, not all of
whichwere designed to evaluate PDR.Wedid not account for individual
study design in our analysis and derived only pooled crude estimates of
prevalence. Our estimates should therefore not be taken to representpopulation prevalence. Lastly, we analysed only sequence data and
were unable to explore differences by sex, age, CD4+ cell count, and
duration of infection, as this information was not available for the
majority of sequences.
In conclusion, we present evidence that the prevalence of PDR has
risen substantially in South Africa in the past few years. Whilst this is
predominantly NNRTI-resistance, there is also evidence of rising levels
of resistance to TDF and FTC/3TC, although the absolute prevalence of
PDR to these drugs remains low. Our ﬁndings support the decision to
transition to a new, DTG-based ﬁrst-line ART regimen. If the association
between neural tube defects and DTG is conﬁrmed, and NNRTIs
continue to be recommended for women of childbearing age [73], this
evidence would suggest the need for additional interventions, such as
pre-treatment genotypic resistance testing or early VL testing. These
ﬁndings also highlight the need for broader strengthening of HIV ser-
vices within the public health system if we are to eliminate HIV/AIDS
as a public health threat by 2030.
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